Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer

Journal of Clinical Oncology

Volumn 34, Issue 23, 2016, Pages 2712-2720

  Frisina, Robert D ^a   Wheeler, Heather E ^b   Fossa, Sophie D ^d   Kerns, Sarah L ^e   Fung, Chunkit ^e   Sesso, Howard D ^g   Monahan, Patrick O ⁱ   Feldman, Darren R ^f   Hamilton, Robert ^j   Vaughn, David J ^k   Beard, Clair J ^h   Budnick, Amy ^f   Johnson, Eileen M ^e   Ardeshir Rouhani fard, Shirin ⁱ   Einhorn, Lawrence H ⁱ   Lipshultz, Steven E ^l   Dolan, M Eileen ^c   Travis, Lois B ⁱ  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j PRINCESS MARGARET HOSPITAL   (Canada)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AUDIOMETRY; AUDITORY THRESHOLD; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVOR; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; GERM CELL TUMOR; HEARING AID; HEARING IMPAIRMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MULTIPLE CYCLE TREATMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; TINNITUS; CASE CONTROL STUDY; CHEMICALLY INDUCED; CONDUCTION DEAFNESS; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; NOISE INJURY; PATHOPHYSIOLOGY; PURE TONE AUDIOMETRY; SEVERITY OF ILLNESS INDEX; SPEECH AUDIOMETRY; SURVIVOR; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUDIOMETRY, PURE-TONE; AUDITORY THRESHOLD; CASE-CONTROL STUDIES; CISPLATIN; FOLLOW-UP STUDIES; HEARING LOSS; HEARING LOSS, CONDUCTIVE; HEARING LOSS, NOISE-INDUCED; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; SEVERITY OF ILLNESS INDEX; SPEECH RECEPTION THRESHOLD TEST; SURVIVORS; TINNITUS; YOUNG ADULT;

EID: 84981272252     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.66.8822     Document Type: Article

References (60)

1. Altekruse S, Kosary C, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2007. Bethesda, MD, National Cancer Institute, 2010
2. DeSantis CE, Lin CC, Mariotto AB, et al: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64:252-271, 2014
3. Elena JW, Travis LB, Simonds NI, et al: Leveraging epidemiology and clinical studies of cancer outcomes: Recommendations and opportunities for translational research. J Natl Cancer Inst 105:85-94, 2013
4. Schell MJ, McHaney VA, Green AA, et al: Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 7:754-760, 1989
5. Osanto S, Bukman A, Van Hoek F, et al: Long-term effects of chemotherapy in patients with tes-ticular cancer. J Clin Oncol 10:574-579, 1992
6. Bokemeyer C, Berger CC, Hartmann JT, et al: Analysis of risk factors for cisplatin-induced ototox-icity in patients with testicular cancer. Br J Cancer 77:1355-1362, 1998
7. Theunissen EA, Zuur CL, Józwiak K, et al: Prediction of hearing loss due to cisplatin chemo-radiotherapy. JAMA Otolaryngol Head Neck Surg 141:810-815, 2015
8. Chen WC, Jackson A, Budnick AS, et al: Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer 106:820-829, 2006
9. Zuur CL, Simis YJ, Lansdaal PE, et al: Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin che-moradiation in patients with locally advanced head and neck cancer. J Clin Oncol 25:3759-3765, 2007
10. Brydøy M, Oldenburg J, Klepp O, et al: Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 101:1682-1695, 2009
11. Glendenning JL, Barbachano Y, Norman AR, et al: Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 116:2322-2331, 2010
12. Case-Eads SL, Travis LB, Fung C, et al: Psychotropic and stimulant medication (PSM) use among testicular cancer survivors (TCS): A multi-institutional clinical study of 680 patients given cisplatin-based chemotherapy. J Clin Oncol 34, 2015(suppl; abstr 242)
13. Fung C, Feldman DR, Hamilton RJ, et al: Cardiovascular disease risk factors among cisplatin-treated testicular cancer survivors (TCS): A multicenter clinical study of U. S. and Canadian patients. J Clin Oncol 33, 2015(suppl 7; abstr 391)
14. Wheeler HE, Travis LB, Budnick A, et al: Comprehensive characterization of cisplatin-related hearing loss in U. S. and Canadian testicular cancer survivors (TCS). J Clin Oncol 33, 2015(suppl; abstr 9570)
15. Zaid MA, Sesso HD, Fung C, et al: Chronic health conditions following cisplatin-based chemotherapy: A multi-institutional study of 680 testicular cancer survivors (TCS). J Clin Oncol 33, 2015(suppl; abstr 9519)
16. Travis LB, Andersson M, Gospodarowicz M, et al: Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 92:1165-1171, 2000
17. Travis LB, Holowaty EJ, Bergfeldt K, et al: Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 340:351-357, 1999
18. Frisina ST, Mapes F, Kim S, et al: Characterization of hearing loss in aged type II diabetics. Hear Res 211:103-113, 2006
19. Guimaraes P, Frisina ST, Mapes F, et al: Progestin negatively affects hearing in aged women. Proc Natl Acad Sci U S A 103:14246-14249, 2006
20. Newman DL, Fisher LM, Ohmen J, et al: GRM7 variants associated with age-related hearing loss based on auditory perception. Hear Res 294:125-132, 2012
21. Knight KR, Kraemer DF, Winter C, et al: Early changes in auditory function as a result of platinum chemotherapy: Use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 25:1190-1195, 2007
22. Chang KW, Chinosornvatana N: Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 28:1788-1795, 2010
23. Abujamra AL, Escosteguy JR, Dall'Igna C, et al: The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy. Pediatr Blood Cancer 60:474-478, 2013
24. American Speech-Language-Hearing Association: Degree of Hearing Loss. www.asha.org/public/hearing/Degree-of-Hearing-Loss
25. Clark JG: Uses and abuses of hearing loss classification. ASHA 23:493-500, 1981
26. Le Prell CG, Hensley BN, Campbell KC, et al: Evidence of hearing loss in a "normally-hearing" college-student population. Int J Audiol 50:S21-S31, 2011(suppl 21)
27. Casali JG, Robinson GS: Noise in Industry: Auditory Effects, Measurement, Regulation and Management. New York, NY, CRC Press, 2003 doi: 10.1201/9780203010457.pt2
28. Crawley MJ. Statistics: An Introduction. New York, NY, Wiley, 2007
29. Shapiro SS, Wilk MB: An analysis of variance test for normality (complete samples). Biometrika 52:591-611, 1965
30. McBride DI, Williams S: Audiometric notch as a sign of noise induced hearing loss. Occup Environ Med 58:46-51, 2001
31. Cruickshanks KJ, Tweed TS, Wiley TL, et al: The 5-year incidence and progression of hearing loss: The epidemiology of hearing loss study. Arch Oto-laryngol Head Neck Surg 129:1041-1046, 2003
32. Engdahl B, Tambs K, Borchgrevink HM, et al: Screened and unscreened hearing threshold levels for the adult population: Results from the Nord-Trøndelag Hearing Loss Study. Int J Audiol 44:213-230, 2005
33. Oldenburg J, Kraggerud SM, Brydøy M, et al: Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med 5:70, 2007
34. Urben SL, Benninger MS, Gibbens ND: Asymmetric sensorineural hearing loss in a community-based population. Otolaryngol Head Neck Surg 120:809-814, 1999
35. Allen PD, Eddins DA: Presbycusis phenotypes form a heterogeneous continuum when ordered by degree and configuration of hearing loss. Hear Res 264:10-20, 2010
36. Palomar García V, Abdulghani Martínez F, Bodet Agustí E, et al: Drug-induced otoxicity: Current status. Acta Otolaryngol 121:569-572, 2001
37. Oldenburg J, Fosså SD, Dahl AA: Scale for chemotherapy-induced long-term neurotoxicity (SCIN): Psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res 15:791-800, 2006
38. Ventry IM, Weinstein BE: The hearing handicap inventory for the elderly: A new tool. Ear Hear 3:128-134, 1982
39. Wickham H: Ggplot2 Elegant Graphics for Data Analysis. New York, NY, Springer Science, 2009
40. Knight KR, Kraemer DF, Winter C, et al: Early changes in auditory function as a result of platinum chemotherapy: Use of extended high-frequency au-diometry and evoked distortion product otoacoustic emissions. J Clin Oncol 25:1190-1195, 2007
41. Knight KR, Kraemer DF, Neuwelt EA: Oto-toxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23:8588-8596, 2005
42. Knudsen LV, Oberg M, Nielsen C, et al: Factors influencing help seeking, hearing aid uptake, hearing aid use and satisfaction with hearing aids: A review of the literature. Trends Amplif 14:127-154, 2010
43. Bertolini P, Lassalle M, Mercier G, et al: Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 26:649-655, 2004
44. Al-Khatib T, Cohen N, Carret AS, et al: Cis-platinum ototoxicity in children, long-term follow up. Int J Pediatr Otorhinolaryngol 74:913-919, 2010
45. Kaltenbach JA: Tinnitus: Models and mechanisms. Hear Res 276:52-60, 2011
46. Zeng FG: An active loudness model suggesting tinnitus as increased central noise and hyperacusis as increased nonlinear gain. Hear Res 295:172-179, 2013
47. Lockwood AH, Salvi RJ, Burkard RF: Tinnitus. N Engl J Med 347:904-910, 2002
48. Centers for Disease Control and Prevention: Noise Induced Hearing Loss. Atlanta, GA, CDC, 2015
49. Demeester K, Van Wieringen A, Hendrickx J J, et al: Audiometric shape and presbycusis. Int J Audiol 48:222-232, 2009
50. Chole RA: Chronic otitis media, mastoiditis, and petrositis, in Flint PW Haughey BH, Lund VJ, et al (eds): Cummings Otolaryngology: Head and Neck Surgery (ed 6). Philadelphia, PA, Elsevier Mosby, 2015, pp 2139-2155
51. Children's Oncology Group: Long-Term Follow-up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancer. www.survivorshipguidelines.org
52. Brock PR, Knight KR, Freyer DR, et al: Platinum-induced ototoxicity in children: A consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol 30:2408-2417, 2012
53. Biro K, Noszek L, Prekopp P, et al: Characteristics and risk factors of cisplatin-induced ototox-icity in testicular cancer patients detected by distortion product otoacoustic emission. Oncology 70:177-184, 2006
54. Cruickshanks KJ, Klein R, Klein BE, et al: Cigarette smoking and hearing loss: The epidemiology of hearing loss study. JAMA 279:1715-1719, 1998
55. National Institute of Occupational Safety and Health: Noise and Hearing Loss Prevention. www.cdc.gov/niosh/topics/noise/toolbox.html
56. Occupational Safety & Health Administration: Occupational Noise Exposure. https://www.osha.gov/SLTC/noisehearingconservation/index.html
57. National Institute on Deafness and Communication Disorders: Hearing Aids. Bethesda, MD, National Institute on Deafness and Other Communication Disorders, 2016
58. Travis LB, Fossa SD, Sesso HD, et al: Chemotherapy-induced peripheral neurotoxicity and ototoxicity: New paradigms for translational geno-mics. J Natl Cancer Inst 106:1-11, 2014
59. Albers P, Albrecht W, Algaba F, et al: Guidelines on testicular cancer: 2015 Update. Eur Urol 68:1054-1068, 2015
60. Hanna NH, Einhorn LH: Testicular cancer-discoveries and updates. N Engl J Med 371:2005-2016, 2014